EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Work disability in patients with newly diagnosed inflammatory bowel disease: Results from the population-based IBSEN III cohort

Charlotte Lund iD, Milada Hagen iD, Vibeke Strande iD, May-Bente Bengtson iD, Tone Bergene Aabrekk iD, Raziye Boyar iD, Svein Oskar Frigstad iD, Kristina I Aass Holten, Øistein Hovde iD, Gert Huppertz-Hauss iD, Bjørn Christian Olsen, Ingunn Johansen iD und 5 weitere

Inflammatory Bowel Diseases · 04.11.2026

DOI: 10.1093/ibd/izag213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 04.11.2026. Verfasst von Charlotte Lund und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Tillotts Pharma, the Foundation Dam, the South-Eastern Health Authorities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to compare the proportion of Crohn’s disease (CD) and ulcerative colitis (UC) patients receiving work disability (WD) benefits with the corresponding proportion in the background population at diagnosis and after 1 year, and to assess associations between selected variables and WD.

Methods

Adults from a population-based inception cohort with WD data at diagnosis and/or 1-year follow-up were included. WD was defined as receiving work assessment allowance (AAP) or disability pension (DP). Relative risks (RRs) for AAP and DP were calculated vs. national registry proportions stratified by age and sex, overall RRs were age standardized. Multivariable logistic regression assessed associations between WD and selected variables.

Results

At diagnosis, risk of AAP was increased for UC (RR, 1.5; 95% confidence interval [CI], 1.1-2.1) and CD patients between 30-39 years old (RR, 2.8; 95% CI, 1.1-5.8). AAP risk was increased at 1-year for both UC (RR, 1.6; 95% CI, 1.1-2.4) and CD (RR, 3.6; 95% CI, 2.4-5.2). DP risk was comparable with the background population. Higher general self-efficacy and health-related quality of life were associated with lower odds of WD, whereas disease-activity variables were not. Older age, comorbidities, and lower education were also associated with increased odds of WD in UC.

Conclusions

After 1 year, patients with UC and CD had increased risk of AAP. Lower general self-efficacy and poorer health-related quality of life were associated with higher WD, suggesting a potential window for targeted interventions to reduce AAP and prevent or delay DP.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseaseulcerative colitiswork disability

Autor:innen und Institutionen

  • Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway.
  • Department of Gastroenterology, Oslo University Hospital, PO Box 4956 Nydalen, 0424 Oslo, Norway.
  • Department of Public Health, Oslo Metropolitan University, PO Box 4 St. Olavs plass, 0130 Oslo, Norway.
  • Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, PO Box 4970 Nydalen, 0440 Oslo, Norway.
  • Department of Gastroenterology, Lovisenberg Diaconal Hospital, PO Box 4970 Nydalen, 0440 Oslo, Norway.
  • Department of Gastroenterology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway.

ORCID-Profile: Charlotte Lund, Milada Hagen, Vibeke Strande, May-Bente Bengtson, Tone Bergene Aabrekk, Raziye Boyar, Svein Oskar Frigstad, Øistein Hovde, Gert Huppertz-Hauss, Ingunn Johansen, Randi Opheim, Gøri Perminow, Roald Torp, Vendel A Kristensen, Marte Lie Høivik

Förderung

  • Takeda Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Tillotts Pharma, the Foundation Dam
  • the South-Eastern Health Authorities

Zitieren

APA

Lund, C., Hagen, M., Strande, V., Bengtson, M. B., Aabrekk, T. B., Boyar, R., Frigstad, S. O., Aass Holten, K. I., Hovde, Ø., Huppertz-Hauss, G., Olsen, B. C., Johansen, I., Opheim, R., Perminow, G., Torp, R., Kristensen, V. A., & Høivik, M. L. (2026). Work disability in patients with newly diagnosed inflammatory bowel disease: Results from the population-based IBSEN III cohort. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag213

Vancouver

Lund C, Hagen M, Strande V, Bengtson MB, Aabrekk TB, Boyar R, et al. Work disability in patients with newly diagnosed inflammatory bowel disease: Results from the population-based IBSEN III cohort. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag213

BibTeX
@article{Lund2026,
  author = {Lund, Charlotte and Hagen, Milada and Strande, Vibeke and Bengtson, May-Bente and Aabrekk, Tone Bergene and Boyar, Raziye and Frigstad, Svein Oskar and Aass Holten, Kristina I and Hovde, Øistein and Huppertz-Hauss, Gert and Olsen, Bjørn Christian and Johansen, Ingunn and Opheim, Randi and Perminow, Gøri and Torp, Roald and Kristensen, Vendel A and Høivik, Marte Lie},
  title = {Work disability in patients with newly diagnosed inflammatory bowel disease: Results from the population-based IBSEN III cohort},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izag213}
}
Kostenlos starten →